ROIV vs. TMO: Roivant Sciences vs. Thermo Fisher Scientific Stock Comparison
How do Roivant Sciences (ROIV) and Thermo Fisher Scientific (TMO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Roivant Sciences (ROIV) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ROIV is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.
Thermo Fisher Scientific (TMO) has more than two decades of public-market history since March 17, 1980, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.
| Profile Item | ROIV | TMO |
|---|---|---|
| Name | Roivant Sciences Ltd. | Thermo Fisher Scientific Inc. |
| Country/Region | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 28.08 billion USD | 257.42 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | December 8, 2020 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ROIV | TMO |
|---|---|---|
| Total Return (1Y) | 96.75% | 24.62% |
| Total Return (3Y, Annualized) | 68.04% | 17.34% |
| Total Return (5Y, Annualized) | 36.73% | 3.11% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ROIV | TMO |
|---|---|---|
| Volatility (1Y, Annualized) | 47.99% | 29.96% |
| Beta (5Y) | 1.17 | 0.83 |
| Max Drawdown (5Y) | -79.22% | -40.95% |
| Avg. Volume (3M) | 7.82M | 2.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ROIV | TMO |
|---|---|---|
| Sharpe Ratio (1Y) | 1.93 | 0.68 |
| Sortino Ratio (1Y) | 4.03 | 1.02 |
Profitability
ROE (TTM)
Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Thermo Fisher Scientific (TMO) reports 13.38%, ranking against industry peers normally.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.52%
- Max
- 109.18%
- Q3
- 6.23%
- ROIV
- -8.52%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.38%
- Max
- 109.18%
- TMO
- 13.38%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Thermo Fisher Scientific (TMO) at 14.94% retains a top-quartile share of revenue as profit, ahead of Roivant Sciences (ROIV) at 0.00%, which keeps about the industry-typical share.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- ROIV
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.94%
- Max
- 18.05%
- TMO
- 14.94%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Thermo Fisher Scientific (TMO) reports 20.19%, ranking against industry peers normally.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-25,408.11%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- ROIV
- -25,408.11%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.19%
- Max
- 83.12%
- TMO
- 20.19%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ROIV | TMO |
|---|---|---|
| ROE (TTM) | -8.52% | 13.38% |
| ROA (TTM) | -16.28% | 5.19% |
| Net Margin (TTM) | 0.00% | 14.94% |
| Operating Margin (TTM) | -25,408.11% | 20.19% |
| Gross Margin (TTM) | 0.00% | 41.26% |
Growth
Revenue Growth
Thermo Fisher Scientific (TMO) at 3.91% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Thermo Fisher Scientific (TMO) reports EPS growth of 7.32%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.
Growth Metrics
| Metric | ROIV | TMO |
|---|---|---|
| Revenue Growth (YoY) | -71.57% | 3.91% |
| Revenue Growth (3Y CAGR) | -36.01% | -0.27% |
| EPS Growth (YoY) | -- | 7.32% |
| EPS Growth (3Y CAGR) | -- | 0.21% |
Financial Strength
Current Ratio (MRQ)
Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while Thermo Fisher Scientific (TMO) at 1.81 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.72
- Max
- 25.13
- ROIV
- 16.72
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TMO
- 1.81
- Min
- 0.10
Debt / Equity (MRQ)
Roivant Sciences (ROIV) at 0.02 carries an industry-typical debt-to-equity mix, while Thermo Fisher Scientific (TMO) at 0.75 uses more debt funding than most peers.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- ROIV
- 0.02
- Q1
- 0.02
- Min
- 0.00
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.75
- Max
- 1.42
- TMO
- 0.75
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ROIV | TMO |
|---|---|---|
| Current Ratio (MRQ) | 16.72 | 1.81 |
| Debt / Equity (MRQ) | 0.02 | 0.75 |
| Net Debt / EBITDA | -- | 2.91 |
Dividends
Dividend Yield (TTM)
Roivant Sciences (ROIV) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27%
- TMO
- 0.27%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Roivant Sciences (ROIV) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.70%
- TMO
- 9.70%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ROIV | TMO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.27% |
| Dividend Payout Ratio (TTM) | 0.00% | 9.70% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Thermo Fisher Scientific (TMO) trades at 36.64 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ROIV
- --
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.64
- Max
- 85.34
- Q3
- 43.46
- TMO
- 36.64
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Thermo Fisher Scientific (TMO) at 5.44 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3,728.61
- ROIV
- 3,728.61
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- TMO
- 5.44
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Thermo Fisher Scientific (TMO) at 4.70 is valued about in line with its industry on P/B ratio, while Roivant Sciences (ROIV) at 6.64 carries an above-peer premium to book — ROIV is pricier on assets.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64
- Max
- 13.53
- ROIV
- 6.64
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- TMO
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ROIV | TMO |
|---|---|---|
| P/E Ratio (TTM) | -- | 36.64 |
| P/S Ratio (TTM) | 3,728.61 | 5.44 |
| P/B Ratio (MRQ) | 6.64 | 4.70 |
| Free Cash Flow Yield (TTM) | -3.98% | 2.50% |